SEARCH RESULTS FOR:
Martín Toscano, Miguel Ángel Delgado, Federico Téllez
MANAGING DIRECTOR, BUSINESS DIRECTOR RE - HIGH PERFORMANCE POLYMERS & BUSINESS DIRECTOR CYPLUS, EVONIK INDUSTRIES DE MÉXICO
Evonik is one of the world's leading specialty chemicals companies.
Paul Hennessey
SENIOR VP SALES, CONTRACT PHARMACAL CORP. (CPC)
Contract Pharmacal Corp. manufactures and packages pharmaceuticals, over-the-counter drugs and dietary supplements.
Robert K. Coughlin
PRESIDENT & CEO, MASSBIO
MassBio’s mission is to advance Massachusetts' leadership in life sciences to grow the industry, add value to the healthcare system and improve patient lives.
Stefan Lepecki
CEO, BRASKEM IDESA
Braskem Idesa was formed by Braskem S.A. (Brazil), the largest producer of thermoplastic resins in America and Grupo Idesa (Mexico), a leader in petrochemicals.
Jennifer Hawks Bland
CEO, NEWYORKBIO
NewYorkBIO brings together New York’s bioscience stakeholders to advance life science research and commercialization.
Thor Kallestad
CEO, DATACLOUD
DataCloud transforms its clients’ drill and blast operations with advanced rock measure-ment technologies and analytics.
Eric Falcand
VICE PRESIDENT, HEAD OF BUSINESS DEVELOPMENT AND LICENSING, SERVIER GROUP
Servier is strengthening its oncology portfolio and widneing its U.S. footprint.
Michel Gilbert
INTERIM PRESIDENT AND CEO & ENGINEER, SOQUEM
SOQUEM was founded in 1965 and has played an instrumental role in Quebec’s mining industry by helping to broaden the range of natural resources under development.
Michel Champagne
PRESIDENT & CEO, SIDEX
SIDEX is an institutional fund that invests in companies engaged in mineral exploration in Québec.
Randy Smallwood
PRESIDENT & CEO, WHEATON PRECIOUS METALS
Wheaton Precious Metals is one of the world’s largest precious metals streaming companies.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
